Your browser doesn't support javascript.
loading
Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma.
Lander, Megan; Abedin, Yasmin; Gabrilovich, Sofia; Marcus, Jenna Z.
Afiliação
  • Lander M; Rutgers New Jersey Medical School, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Newark, NJ, United States.
  • Abedin Y; Division of Gynecologic Oncology Rutgers, New Jersey Medical School, 185 South Orange Ave, MSB E-536, Newark, NJ 07103, United States.
  • Gabrilovich S; Rutgers New Jersey Medical School, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology and Women's Health, Newark, NJ, United States.
  • Marcus JZ; Division of Gynecologic Oncology Rutgers, New Jersey Medical School, 185 South Orange Ave, MSB E-536, Newark, NJ 07103, United States.
Gynecol Oncol Rep ; 32: 100552, 2020 May.
Article em En | MEDLINE | ID: mdl-32140531
This case report describes a patient who developed severe hypertriglyceridemia (1871 mg/dL) and hyperlipidemia (LDL 132 mg/dL) during intraperitoneal (IP) administration of cisplatin and paclitaxel as adjuvant treatment for stage IIIC fallopian tube carcinoma. After an evaluation with her primary care physician, she was treated with gemfibrozil and rosuvastatin for the duration of her treatment. There was complete resolution of hypertriglyceridemia after completion of chemotherapy. This adverse event is rare and has not been reported in the literature with this chemotherapeutic regimen. A pre-chemotherapy evaluation for dyslipidemia may be beneficial in the detection and monitoring of this condition.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article